BR9909868A - Paroxetine ascorbate - Google Patents

Paroxetine ascorbate

Info

Publication number
BR9909868A
BR9909868A BR9909868-7A BR9909868A BR9909868A BR 9909868 A BR9909868 A BR 9909868A BR 9909868 A BR9909868 A BR 9909868A BR 9909868 A BR9909868 A BR 9909868A
Authority
BR
Brazil
Prior art keywords
paroxetine ascorbate
paroxetine
ascorbate
useful
treatment
Prior art date
Application number
BR9909868-7A
Other languages
Portuguese (pt)
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9909868A publication Critical patent/BR9909868A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ASCORBATO DE PAROXETINA" O ascorbato de paroxetina é útil no tratamento de alguns distúrbios da CNS."PAROXETINE ASCORBATE" Paroxetine ascorbate is useful in the treatment of some CNS disorders.

BR9909868-7A 1998-04-25 1999-04-23 Paroxetine ascorbate BR9909868A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (1)

Publication Number Publication Date
BR9909868A true BR9909868A (en) 2000-12-19

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909868-7A BR9909868A (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Country Status (20)

Country Link
EP (1) EP1089995A1 (en)
JP (1) JP2002513019A (en)
KR (1) KR20010042977A (en)
CN (1) CN1297448A (en)
AP (1) AP2000001963A0 (en)
AU (1) AU3618499A (en)
BG (1) BG104940A (en)
BR (1) BR9909868A (en)
CA (1) CA2330055A1 (en)
EA (1) EA200001104A1 (en)
GB (1) GB9808896D0 (en)
HU (1) HUP0102116A3 (en)
ID (2) ID26083A (en)
IL (1) IL139081A0 (en)
NO (1) NO20005352L (en)
PL (1) PL343677A1 (en)
SK (1) SK15912000A3 (en)
TR (1) TR200003084T2 (en)
WO (1) WO1999055698A1 (en)
ZA (1) ZA200005912B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
EP2272501B1 (en) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
CN110607554B (en) * 2018-10-30 2024-03-22 中国科学院化学研究所 Method for preparing medicine or medicine intermediate monocrystal or amorphous substance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE3688827T2 (en) * 1985-10-25 1994-03-31 Beecham Group Plc Piperidine derivative, its manufacture and its use as a medicine.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (en) * 1996-02-29 1999-07-01 Ferrer Int NEW PROCEDURE FOR OBTAINING (-) - TRANS -N-P-FLUOROBENZOILMETIL-4- (P-FLUOROFENIL) -3- ((3,4- (METHYLENDIOXI) PHENOXI) METHYL) -PIPERIDINE.

Also Published As

Publication number Publication date
ID26654A (en) 2001-01-25
TR200003084T2 (en) 2001-02-21
HUP0102116A2 (en) 2002-05-29
SK15912000A3 (en) 2001-04-09
KR20010042977A (en) 2001-05-25
ID26083A (en) 2000-11-23
BG104940A (en) 2001-09-28
EP1089995A1 (en) 2001-04-11
NO20005352D0 (en) 2000-10-24
IL139081A0 (en) 2001-11-25
WO1999055698A1 (en) 1999-11-04
GB9808896D0 (en) 1998-06-24
JP2002513019A (en) 2002-05-08
CN1297448A (en) 2001-05-30
EA200001104A1 (en) 2001-04-23
ZA200005912B (en) 2001-12-19
NO20005352L (en) 2000-10-24
AU3618499A (en) 1999-11-16
PL343677A1 (en) 2001-08-27
HUP0102116A3 (en) 2002-12-28
AP2000001963A0 (en) 2000-12-31
CA2330055A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
CY2018020I2 (en) TREATMENT OF ROMRE'S DISEASE
MX9201419A (en) BENZO DERIVATIVES ISOXAZOL-PIPERIDINE.
IT244967Y1 (en) DYNAMIC ORTHOSIS FOR THE CONSERVATIVE TREATMENT OF FEMOROUS ROTULA OF THE KNEE
ES2191102T3 (en) USEFUL PEPTIDYL HETEROCICLES IN THE TREATMENT OF THROMBIN-RELATED AFFECTIONS.
TR200000059T2 (en) Pyridine derivatives
DE69925306D1 (en) TREATMENT OF HYDROCARBONGAS
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
NO20005884D0 (en) Combination therapy for the treatment of bipolar disorders
ES2184077T3 (en) NEW FENANTRIDINS REPLACED IN POSITION 6.
CH1143977H1 (en) 2-Oxy-benzoxazine-4-ones for the treatment of obesity
FI972919A (en) Indole derivatives useful in the treatment of osteoporosis
NO20005885D0 (en) Combination therapy for the treatment of refractory depression
DZ3014A1 (en) Medicines for the treatment of hypertension.
FI974640A0 (en) 1,6-Disubstituted isochromanes for the treatment of migraine
ID27214A (en) TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
DE58902899D1 (en) 2 ', 3'-DIDEOXYPURINNUCLEOSIDE / PURINNUCLEOSIDE-PHOSPHORYLASE INHIBITOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR.
DE69735417D1 (en) 2,5-DIHYDROXYBENZYLSULFON DERIVATIVES FOR THE TREATMENT OF SEXUAL DISORDERS
BR9808299A (en) The use of levobupivacaìna or ropivacaìna for the treatment of migraine
BR9909868A (en) Paroxetine ascorbate
NO20011892D0 (en) 3-tetrahydropyridin-4-yl indoles for the treatment of psychotic disorders
NO20012612D0 (en) Isonipecotamides for the treatment of integrin-mediated disorders
FR2781118B1 (en) BODY EQUIPMENT
DE69917445D1 (en) CLEANING CARBOXALDEHYDE
NO20025760L (en) S-methyl-dihydro-ziprasidone for the treatment of psychiatric and ocular disorders

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]